Top 25 Companies in Global Amyotrophic Lateral Sclerosis Treatment Market: Global Share, Market Size, Revenue Report (2024–2035)
RELEASE DATE: Mar 2026 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Introduction
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that damages motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and eventually respiratory failure. Treatment focuses on slowing disease progression and improving quality of life through medications such as Riluzole and Edaravone, along with supportive therapies including physical rehabilitation, respiratory support, and assistive communication technologies. ALS therapies are widely applied in neurology, hospital care, and home-based disease management programs. Governments worldwide are supporting research through initiatives such as the National Institutes of Health ALS research funding programs and collaborative global clinical trials. Recent developments include gene-targeted therapies and the 2023 approval of Tofersen for specific ALS mutations. Growing awareness, improved diagnostics, and increasing investment in neurodegenerative disease research are key factors driving advancements in ALS treatment.
In June 2024, Mitsubishi Tanabe Pharma Corporation transferred its European argatroban business to Ethypharm, focusing on Radicava’s treatment agent for ALS in the region.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Amyotrophic Lateral Sclerosis Treatment Market.
Market Segmentation
Global Amyotrophic Lateral Sclerosis Treatment Market Size, Share, and COVID-19 Impact Analysis, By Type (Sporadic Amyotrophic Lateral Sclerosis Treatment and Familial Amyotrophic Lateral Sclerosis Treatment), By Treatment Type (Medication-Based Therapy, Gene / Antisense Oligonucleotide Therapy, Stem Cell Therapy, and Symptomatic Treatment), By Drug Type (Riluzole, Edaravone, Sodium Phenylbutyrate/Taurursodiol, and Other Emerging Therapies), By Route of Administration (Oral, Intravenous, Subcutaneous, and Intrathecal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By End User / Application (Hospitals, Specialty Neurology Clinics / ALS Centers, Homecare Settings, and Research and Academic Institutes), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025–2035.
Amyotrophic Lateral Sclerosis Treatment Market Size & Statistics
- The Market Size for Amyotrophic Lateral Sclerosis Treatment Was Estimated to be worth USD 678.53 Million in 2024.
- The Market is Going to Expand at a CAGR of 5.24% between 2025 and 2035.
- The Global Amyotrophic Lateral Sclerosis Treatment Market Size is anticipated to reach USD 1189.46 Million by 2035.
- North America is expected to generate the highest demand during the forecast period in the Amyotrophic Lateral Sclerosis Treatment Market
- Asia Pacific is expected to grow the fastest during the forecast period in the Amyotrophic Lateral Sclerosis Treatment Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the amyotrophic lateral sclerosis treatment market. The region’s growth is driven by increasing prevalence of neurodegenerative disorders, improving healthcare infrastructure, rising awareness and diagnosis of ALS, expanding access to advanced neurological therapies, and growing investments in biotechnology and pharmaceutical research. Governments in countries such as China, Japan, and India are supporting neurological disease research programs and improving patient access to innovative treatments. In addition, the presence of a large patient population, increasing healthcare spending, and expanding clinical trial activities are contributing to the rapid growth of ALS treatment adoption across the region.
North America is expected to generate the highest demand during the forecast period in the amyotrophic lateral sclerosis treatment market. The region leads due to advanced healthcare systems, strong presence of major pharmaceutical and biotechnology companies, high awareness and early diagnosis of ALS, and continuous investment in neurodegenerative disease research. Supportive regulatory frameworks, increasing clinical trials, and the availability of approved therapies such as riluzole and edaravone further strengthen the market demand. Additionally, strong funding from research organizations and government agencies is accelerating the development and commercialization of innovative ALS treatments in the region.
Ready to lead the Amyotrophic Lateral Sclerosis Treatment Market
Discover the regional trends and growth factors shaping the industry. We’re here to assist with expert, personalized data.
Call +1 303 800 4326 or Send us a message for a personalized consultation.
Top 10 Trends in the Amyotrophic Lateral Sclerosis Treatment Market
• Increasing Development of Gene and Antisense Therapies
• Rising Investment in Neurodegenerative Disease Research
• Growing Adoption of Disease-Modifying Therapies
• Expansion of Clinical Trials for Novel ALS Drugs
• Increasing Use of Advanced Diagnostic Technologies
• Growth in Personalized and Precision Medicine
• Expansion of Stem Cell-Based Treatment Research
• Rising Awareness and Early Diagnosis Programs
• Strategic Collaborations Between Pharma and Research Institutes
• Advancements in Digital Health and Remote Patient Monitoring
Top 5 Trends
1.Increasing Development of Gene and Antisense Therapies
Researchers and biotechnology companies are focusing on gene-targeted treatments and antisense oligonucleotide therapies to address genetic mutations associated with ALS. These innovative therapies aim to slow disease progression and provide targeted treatment for specific patient groups.
2.Rising Investment in Neurodegenerative Disease Research
Governments, pharmaceutical companies, and research organizations are increasing funding for ALS research to accelerate drug discovery and clinical development. Growing investment is supporting new therapeutic approaches and improving understanding of disease mechanisms.
3.Growing Adoption of Disease-Modifying Therapies
The ALS treatment landscape is shifting toward disease-modifying therapies designed to slow the progression of motor neuron degeneration. Newly approved drugs and emerging treatment options are improving patient management and expanding available therapeutic strategies.
4.Expansion of Clinical Trials for Novel ALS Drugs
A growing number of global clinical trials are evaluating new treatment candidates, including gene therapies, stem cell therapies, and neuroprotective drugs. These trials are driving innovation and increasing the likelihood of new treatment approvals in the coming years.
5.Growth in Personalized and Precision Medicine
Advancements in genetic testing and biomarker research are enabling more personalized treatment approaches for ALS patients. Precision medicine strategies help identify patient-specific therapies, improving treatment effectiveness and supporting better disease management outcomes.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Amyotrophic Lateral Sclerosis Treatment Market.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the Amyotrophic Lateral Sclerosis Treatment market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 25 Companies Leading the Amyotrophic Lateral Sclerosis Treatment Market
- Biogen Inc.
- Mitsubishi Tanabe Pharma Corporation
- Amylyx Pharmaceuticals, Inc.
- F. Hoffmann-La Roche Ltd
- Ionis Pharmaceuticals, Inc.
- Denali Therapeutics Inc.
- Alexion Pharmaceuticals, Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Eisai Co., Ltd.
- AbbVie Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Astellas Pharma Inc.
- Cytokinetics, Incorporated
- BrainStorm Cell Therapeutics Inc.
- Verge Genomics Inc.
- Apellis Pharmaceuticals, Inc.
- NeuroSense Therapeutics Ltd.
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Amyotrophic Lateral Sclerosis Treatment Market.
1.Biogen Inc.
Headquarters: Cambridge, Massachusetts, United States
Biogen Inc. is a leading biotechnology company focusing on neurological and neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS). The company has played a major role in developing innovative ALS therapies, including the antisense oligonucleotide therapy Tofersen, designed to target genetic mutations linked to ALS. Biogen invests heavily in neuroscience research, gene therapy platforms, and advanced drug development technologies. Through collaborations with research institutions and biotechnology partners, the company continues to expand its pipeline of treatments aimed at slowing disease progression and improving the quality of life for ALS patients worldwide.
2.Mitsubishi Tanabe Pharma Corporation
Headquarters: Osaka, Japan
Mitsubishi Tanabe Pharma Corporation is a major pharmaceutical company recognized for developing therapies for neurological and rare diseases. The company developed Edaravone, one of the key drugs approved for ALS treatment, which helps reduce oxidative stress in motor neurons and slow disease progression. Mitsubishi Tanabe continues to invest in research aimed at improving neurological disease management and expanding treatment accessibility worldwide. With strong expertise in neuropharmacology and global partnerships, the company remains a significant contributor to advancements in ALS therapy and patient care.
3.Amylyx Pharmaceuticals
Headquarters: Cambridge, Massachusetts, United States
Amylyx Pharmaceuticals is a biotechnology company focused on developing treatments for neurodegenerative diseases such as ALS and Alzheimer’s disease. The company developed the therapy sodium phenylbutyrate/taurursodiol, designed to protect neurons from cell death and slow ALS progression. Amylyx emphasizes innovative approaches that target underlying cellular stress pathways involved in neurodegeneration. Through clinical research and partnerships with global healthcare organizations, the company is contributing to the development of disease-modifying therapies that aim to improve survival and quality of life for ALS patients.
4.F. Hoffmann-La Roche Ltd
Headquarters: Basel, Switzerland
Roche is a global healthcare company with strong expertise in pharmaceuticals and biotechnology. The company supports research and development of treatments for neurological disorders, including ALS, through collaborations with biotechnology firms and academic institutions. Roche’s advanced drug discovery technologies, genomic research capabilities, and clinical development programs contribute to the exploration of innovative therapies targeting neurodegenerative diseases. With a global presence and strong investment in neuroscience research, Roche plays an important role in advancing ALS drug development.
5.Ionis Pharmaceuticals
Headquarters: Carlsbad, California, United States
Ionis Pharmaceuticals specializes in antisense oligonucleotide technology used to develop targeted therapies for genetic diseases. The company has collaborated on the development of ALS treatments aimed at modifying disease-causing genes. Ionis focuses on RNA-targeted therapeutics designed to regulate protein production linked to neurological disorders. Through its advanced genetic medicine platform and partnerships with major pharmaceutical companies, Ionis continues to support the development of precision therapies for ALS and other neurodegenerative conditions.
Are you ready to discover more about the Amyotrophic Lateral Sclerosis Treatment market?
The report provides an in-depth analysis of the leading companies operating in the global Amyotrophic Lateral Sclerosis Treatment market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Unlock exclusive market insights—Download the Brochure now and dive deeper into the future of the Amyotrophic Lateral Sclerosis Treatment Market.
Company Profiles
1.Biogen Inc.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
2.Mitsubishi Tanabe Pharma Corporation
3.Amylyx Pharmaceuticals, Inc.
4.F. Hoffmann-La Roche Ltd
5.Ionis Pharmaceuticals, Inc.
6.Denali Therapeutics Inc.
7.Alexion Pharmaceuticals, Inc.
8.Novartis AG
9.Pfizer Inc.
10.Others.
Other Indusrty Reports :
https://www.sphericalinsights.com/reports/germany-electric-bus-market
https://www.sphericalinsights.com/reports/germany-light-commercial-vehicle-market
https://www.sphericalinsights.com/reports/germany-recreational-boating-market
https://www.sphericalinsights.com/reports/germany-surgical-equipment-market
https://www.sphericalinsights.com/reports/furnace-filters-market
Conclusion
The global amyotrophic lateral sclerosis treatment market is witnessing steady growth, driven by the increasing prevalence of neurodegenerative diseases, rising awareness about early diagnosis, and growing investment in neurological research. Amyotrophic lateral sclerosis treatment focuses on slowing disease progression, managing symptoms, and improving the quality of life for patients through medications, supportive therapies, and emerging advanced treatment approaches. Continuous advancements in biotechnology, gene-targeted therapies, and clinical research are expanding treatment possibilities for ALS patients. In addition, increasing government support, research funding, and collaborations between pharmaceutical companies and research institutions are accelerating drug development. Leading companies such as Biogen Inc., Mitsubishi Tanabe Pharma Corporation, and Amylyx Pharmaceuticals, Inc. are strengthening their market presence through innovation and clinical advancements. Overall, the ALS treatment market is expected to grow as new therapies and improved healthcare access enhance disease management worldwide.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?